Sponsor Pipeline

Sangamo Therapeutics Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
4
Active Trials
1
Recruiting
1
Disease Areas
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-14 NCT04628871
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
critical Trial terminated
2026-08-14 NCT04628871
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
critical Trial terminated: Sangamo declared Chapter 11 Bankruptcy on 23Jun2026 and terminated the study on 21Jul2026.
2026-08-14 NCT04628871
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
date change Primary completion moved earlier: 2030-01-01 -> 2026-06-17
2026-08-14 NCT04628871
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
date change Completion moved earlier: 2030-01-01 -> 2026-06-17
Active Trials by Phase
Phase 1/2
1
Not specified
3
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT06980948 Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy… Chronic Neuropathic Pain Recruiting
Not specified
NCT05039866 Long-Term Follow-up of Subjects Who Were Treated With ST-920 Fabry Disease Enrolling by Invitation
NCT05145062 Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously… Blood and Lymphatic Diseases Active, Not Recruiting
NCT05987527 Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term) Kidney Transplant Rejection Active, Not Recruiting
Disease Areas
Get alerts when Sangamo Therapeutics's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free